Bita Shahrami
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bita Shahrami has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Farhad Najmeddin
Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
7 shared publications - Kourosh Sadeghi
Department of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
7 shared publications - Mohammad Vaezi
Hematology, Oncology, and Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology, and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran
7 shared publications - AmirAhmad Arabzadeh
Department of Surgery, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran
6 shared publications - Mojtaba Mojtahedzadeh
Department of Clinical Pharmacy, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran
6 shared publications - Romina Kaveh-Ahangaran
Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran
5 shared publications
Latest Publications
- 4 October 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (10) , 1054
N-acetylcysteine mouthwash for prevention of oral mucositis in hematopoietic cell transplant recipients: a double-blind randomized controlled trial
- 4 October 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (10) , 1054
N-acetylcysteine mouthwash for prevention of oral mucositis in hematopoietic cell transplant recipients: a double-blind randomized controlled trial
- Open Access
- 1 September 2026
- Published by Springer Nature in BMC Infectious Diseases
Antimicrobial lock therapy for catheter-related infections in cancer patients: a systematic review and meta-analysis
- 1 September 2026
- Published by Springer Nature in BMC Infectious Diseases
Open AccessAntimicrobial lock therapy for catheter-related infections in cancer patients: a systematic review and meta-analysis
- 16 February 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (3) , 206
High-dose vitamin C supplementation in patients undergoing allogeneic hematopoietic stem cell transplantation: A pilot randomized, triple-blind, placebo-controlled trial
Purpose Allogenic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment for hematological disorders but often results in micronutrients deficiency and complications. Vitamin C, a potent antioxidant, may improve endothelial function, tissue protection, and immune recovery. This study evaluated the effects of early high-dose vitamin C supplementation on plasma vitamin C levels and post-HSCT complications. Methods In this pilot, triple-blind, placebo-controlled trial, 31 adult allo-HSCT patients were randomized to receive intravenous vitamin C (50 mg/kg/day) or placebo from day + 1 to + 14, followed by oral vitamin C (500 mg/day) or placebo until day + 100. Plasma vitamin C levels were measured at days 0, + 7, + 15, and discharge. Patients were monitored for post-HSCT complications until day + 100. Results Plasma vitamin C levels were significantly higher in the vitamin C group at all time points (P < 0.001). Trends toward reduced acute graft-versus-host disease (33% vs. 44%), lower oral mucositis severity (46.6% vs. 62.5%), and shorter duration (7.5 ± 3.6 vs. 9.1 ± 3.7 days) were observed, though not statistically significant. No significant adverse events were reported. Conclusion High-dose vitamin C effectively corrected plasma levels, and while trends toward reduced complications were observed in allo-HSCT patients, larger trials are needed to confirm these findings. Graphical abstract
- 16 February 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (3) , 206
High-dose vitamin C supplementation in patients undergoing allogeneic hematopoietic stem cell transplantation: A pilot randomized, triple-blind, placebo-controlled trial
Purpose Allogenic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment for hematological disorders but often results in micronutrients deficiency and complications. Vitamin C, a potent antioxidant, may improve endothelial function, tissue protection, and immune recovery. This study evaluated the effects of early high-dose vitamin C supplementation on plasma vitamin C levels and post-HSCT complications. Methods In this pilot, triple-blind, placebo-controlled trial, 31 adult allo-HSCT patients were randomized to receive intravenous vitamin C (50 mg/kg/day) or placebo from day + 1 to + 14, followed by oral vitamin C (500 mg/day) or placebo until day + 100. Plasma vitamin C levels were measured at days 0, + 7, + 15, and discharge. Patients were monitored for post-HSCT complications until day + 100. Results Plasma vitamin C levels were significantly higher in the vitamin C group at all time points (P < 0.001). Trends toward reduced acute graft-versus-host disease (33% vs. 44%), lower oral mucositis severity (46.6% vs. 62.5%), and shorter duration (7.5 ± 3.6 vs. 9.1 ± 3.7 days) were observed, though not statistically significant. No significant adverse events were reported. Conclusion High-dose vitamin C effectively corrected plasma levels, and while trends toward reduced complications were observed in allo-HSCT patients, larger trials are needed to confirm these findings. Graphical abstract
- Open Access
- 8 May 2025
- Published by SAGE Publications in Therapeutic Advances in Drug Safety
- Vol. 16
Drug-induced fever in post-surgical patients: a systematic review of case reports
Background: Fever is a common postoperative complication, typically caused by aseptic inflammation or infection. However, drug-induced fever (DIF) is an underdiagnosed etiology that should be considered in the differential diagnosis, especially in patients receiving complex medication regimens post-surgery. Objectives: This systematic review aims to assess the current literature on DIF in post-surgical patients to improve diagnostic accuracy and patient care. Design: Systematic review of case reports and case series. Data sources and methods: This systematic review was conducted following the PRISMA 2020 guidelines. We included case reports and series involving post-surgical patients with fever linked to drug administration. Studies were retrieved from the PubMed, Scopus, Embase, and Web of Science databases, as well as gray literature sources. Quality and bias were assessed using the Joanna Briggs Institute (JBI) critical appraisal tools. Results: A total of 16 studies (14 case reports and 2 case series) involving 23 patients were included. The most frequently implicated drugs were propofol, morphine, and cephalosporins. Fever onset ranged from immediate postoperative to several days later, with varied patterns, including intermittent, remittent, and continuous fever. The majority of patients recovered after drug discontinuation, although two cases resulted in death. Conclusion: DIF is one of the causes of postoperative fever. Early identification and cessation of the offending drug are crucial for resolving the fever and preventing severe complications. Clinicians must remain vigilant in diagnosing DIF to improve patient outcomes post-surgery.
- 8 May 2025
- Published by SAGE Publications in Therapeutic Advances in Drug Safety
- Vol. 16
Open AccessDrug-induced fever in post-surgical patients: a systematic review of case reports
Background: Fever is a common postoperative complication, typically caused by aseptic inflammation or infection. However, drug-induced fever (DIF) is an underdiagnosed etiology that should be considered in the differential diagnosis, especially in patients receiving complex medication regimens post-surgery. Objectives: This systematic review aims to assess the current literature on DIF in post-surgical patients to improve diagnostic accuracy and patient care. Design: Systematic review of case reports and case series. Data sources and methods: This systematic review was conducted following the PRISMA 2020 guidelines. We included case reports and series involving post-surgical patients with fever linked to drug administration. Studies were retrieved from the PubMed, Scopus, Embase, and Web of Science databases, as well as gray literature sources. Quality and bias were assessed using the Joanna Briggs Institute (JBI) critical appraisal tools. Results: A total of 16 studies (14 case reports and 2 case series) involving 23 patients were included. The most frequently implicated drugs were propofol, morphine, and cephalosporins. Fever onset ranged from immediate postoperative to several days later, with varied patterns, including intermittent, remittent, and continuous fever. The majority of patients recovered after drug discontinuation, although two cases resulted in death. Conclusion: DIF is one of the causes of postoperative fever. Early identification and cessation of the offending drug are crucial for resolving the fever and preventing severe complications. Clinicians must remain vigilant in diagnosing DIF to improve patient outcomes post-surgery.
- Open Access
- 28 March 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (7) , e70837
Efficacy of Low‐Dose Fluconazole for Primary Prophylaxis of Invasive Candida Infections in Patients With Acute Leukemia: A Double‐Blind Randomized Clinical Trial
Background: Invasive fungal infections (IFIs), particularly Candida infections, are a significant cause of morbidity and mortality in patients with acute leukemia. While fluconazole is widely used for prophylaxis, the optimal dosing regimen remains uncertain. This study aimed to evaluate the efficacy of low‐dose fluconazole for primary prophylaxis against invasive Candida infections in patients with acute leukemia receiving intensive chemotherapy.Methods: A double‐blind, randomized clinical trial was conducted with patients diagnosed with acute leukemia. Patients were assigned to receive either low‐dose (150 mg/day) or standard high‐dose (400 mg/day) fluconazole for primary prophylaxis against invasive Candida infections during intensive chemotherapy. The primary outcomes were the efficacy of antifungal prophylaxis and the safety profile.Results: A total of 120 patients (60 per group) were enrolled. The overall incidence of Candida infections was similar between the groups (p = 0.615). Candida colonization was higher in the low‐dose fluconazole group during the first week, particularly with non‐albicans Candida at oral and subaxillary sites (p < 0.001). However, by the third week, both groups showed a significant decline in colonization, with the reduction in the oral cavity being statistically significant (p = 0.03). Aspergillosis occurred in 38.3% of patients, with no significant difference between groups (p > 0.99). Adverse events were similar in both groups (p > 0.05).Conclusion: Low‐dose fluconazole is an effective alternative to high‐dose regimens for preventing Candida infections in acute leukemia patients, with similar efficacy and safety. The rising threat of aspergillosis highlights the need for targeted prophylaxis. Further research is needed to refine strategies for high‐risk patients.Trial Registration: Iranian Registry of Clinical Trials (IRCT) number: IRCT20140818018842N37
- 28 March 2025
- Published by Wiley in Cancer Medicine
- Vol. 14 (7) , e70837
Open AccessEfficacy of Low‐Dose Fluconazole for Primary Prophylaxis of Invasive Candida Infections in Patients With Acute Leukemia: A Double‐Blind Randomized Clinical Trial
Background: Invasive fungal infections (IFIs), particularly Candida infections, are a significant cause of morbidity and mortality in patients with acute leukemia. While fluconazole is widely used for prophylaxis, the optimal dosing regimen remains uncertain. This study aimed to evaluate the efficacy of low‐dose fluconazole for primary prophylaxis against invasive Candida infections in patients with acute leukemia receiving intensive chemotherapy.Methods: A double‐blind, randomized clinical trial was conducted with patients diagnosed with acute leukemia. Patients were assigned to receive either low‐dose (150 mg/day) or standard high‐dose (400 mg/day) fluconazole for primary prophylaxis against invasive Candida infections during intensive chemotherapy. The primary outcomes were the efficacy of antifungal prophylaxis and the safety profile.Results: A total of 120 patients (60 per group) were enrolled. The overall incidence of Candida infections was similar between the groups (p = 0.615). Candida colonization was higher in the low‐dose fluconazole group during the first week, particularly with non‐albicans Candida at oral and subaxillary sites (p < 0.001). However, by the third week, both groups showed a significant decline in colonization, with the reduction in the oral cavity being statistically significant (p = 0.03). Aspergillosis occurred in 38.3% of patients, with no significant difference between groups (p > 0.99). Adverse events were similar in both groups (p > 0.05).Conclusion: Low‐dose fluconazole is an effective alternative to high‐dose regimens for preventing Candida infections in acute leukemia patients, with similar efficacy and safety. The rising threat of aspergillosis highlights the need for targeted prophylaxis. Further research is needed to refine strategies for high‐risk patients.Trial Registration: Iranian Registry of Clinical Trials (IRCT) number: IRCT20140818018842N37
- Open Access
- 1 January 2025
- Published by Wiley in European Journal of Cancer Care
- Vol. 2025 (1)
The Role of Antioxidant Supplementation in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review
Background: Patients undergoing hematopoietic stem cell transplantation (HSCT) often face complications during the acute posttransplantation period. HSCT complications are linked to oxidative stress (OS) mechanisms due to accumulation of reactive oxygen species. Researchers hypothesize that antioxidant levels may modify OS immediately after HSCT. Objective: This systematic review aimed to collect evidence on the role of antioxidant supplementation in determining the outcomes and complications of HSCT. Study Design: A systematic search of two databases was conducted, including studies published until January 2024. Inclusion criteria involved clinical original studies focusing on adults and children undergoing HSCT who received antioxidant supplementation during and/or after HSCT. Results: The review included 20 eligible studies, featuring antioxidants such as N‐acetyl cysteine, vitamin C, zinc, selenium, vitamin E, and melatonin. Outcomes examined included immune system recovery, engraftment, oral mucositis, liver toxicity, nephrotoxicity, and acute graft‐versus‐host disease. The findings indicate an unclear association between antioxidant use and complications after HSCT. The certainty of evidence for these outcomes was low or very low. Conclusions: Although the use of antioxidants in HSCT patients has been deemed safe and has even been associated with positive outcomes in some studies, the necessity for antioxidant supplementation during HSCT remains uncertain. Further large randomized controlled trials are necessary to ascertain antioxidant requirements and establish precise supplementation protocols for HSCT patients.
- 1 January 2025
- Published by Wiley in European Journal of Cancer Care
- Vol. 2025 (1)
Open AccessThe Role of Antioxidant Supplementation in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review
Background: Patients undergoing hematopoietic stem cell transplantation (HSCT) often face complications during the acute posttransplantation period. HSCT complications are linked to oxidative stress (OS) mechanisms due to accumulation of reactive oxygen species. Researchers hypothesize that antioxidant levels may modify OS immediately after HSCT. Objective: This systematic review aimed to collect evidence on the role of antioxidant supplementation in determining the outcomes and complications of HSCT. Study Design: A systematic search of two databases was conducted, including studies published until January 2024. Inclusion criteria involved clinical original studies focusing on adults and children undergoing HSCT who received antioxidant supplementation during and/or after HSCT. Results: The review included 20 eligible studies, featuring antioxidants such as N‐acetyl cysteine, vitamin C, zinc, selenium, vitamin E, and melatonin. Outcomes examined included immune system recovery, engraftment, oral mucositis, liver toxicity, nephrotoxicity, and acute graft‐versus‐host disease. The findings indicate an unclear association between antioxidant use and complications after HSCT. The certainty of evidence for these outcomes was low or very low. Conclusions: Although the use of antioxidants in HSCT patients has been deemed safe and has even been associated with positive outcomes in some studies, the necessity for antioxidant supplementation during HSCT remains uncertain. Further large randomized controlled trials are necessary to ascertain antioxidant requirements and establish precise supplementation protocols for HSCT patients.
- Open Access
- 1 January 2025
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 2025 (1)
Identification and Resolution of Drug‐Related Problems by Clinical Pharmacist Interventions in an Occupational Health Setting: A Study on Pharmacy Staff
Background: Occupational health programs play a critical role in maintaining employee well‐being, particularly for healthcare workers exposed to unique risks. Clinical pharmacists are well‐positioned to address drug‐related problems (DRPs) in these settings, yet their role in occupational health remains underexplored. This study assesses the frequency and resolution of DRPs following clinical pharmacist interventions among pharmacy staff in an occupational health setting. Methods: This experimental study was conducted at the 13‐Aban Pharmacotherapy Clinic of Tehran University of Medical Sciences, Tehran, Iran. Pharmacy staff with chronic diseases or abnormal test results was identified based on medical records. A single clinical pharmacist reviewed DRPs using the DOCUMENT classification system, provided interventions, and followed up. Recommendations were made directly to participants, and adherence to these recommendations was assessed. Data were analyzed using descriptive statistics and correlation tests. Results: Among 601 medical records reviewed, 239 participants met inclusion criteria, and 139 attended pharmacotherapy visits. A total of 277 DRPs were identified, averaging 1.99 DRPs per participant. The most common DRPs were the need for preventative therapy (37.2%), untreated conditions (15.9%), and laboratory monitoring (14.8%). A total of 443 recommendations were provided to participants, with an adherence rate of 76.4%. Among those who fully adhered to the recommendations, 97.2% of DRPs were resolved. While adherence was initially higher among female participants, overall compliance rates did not significantly differ by gender. Conclusion: Clinical pharmacist interventions effectively identified and resolved DRPs among pharmacy staff, improving medication management. These findings highlight the value of integrating clinical pharmacists into occupational health programs to enhance medication safety and adherence.
- 1 January 2025
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 2025 (1)
Open AccessIdentification and Resolution of Drug‐Related Problems by Clinical Pharmacist Interventions in an Occupational Health Setting: A Study on Pharmacy Staff
Background: Occupational health programs play a critical role in maintaining employee well‐being, particularly for healthcare workers exposed to unique risks. Clinical pharmacists are well‐positioned to address drug‐related problems (DRPs) in these settings, yet their role in occupational health remains underexplored. This study assesses the frequency and resolution of DRPs following clinical pharmacist interventions among pharmacy staff in an occupational health setting. Methods: This experimental study was conducted at the 13‐Aban Pharmacotherapy Clinic of Tehran University of Medical Sciences, Tehran, Iran. Pharmacy staff with chronic diseases or abnormal test results was identified based on medical records. A single clinical pharmacist reviewed DRPs using the DOCUMENT classification system, provided interventions, and followed up. Recommendations were made directly to participants, and adherence to these recommendations was assessed. Data were analyzed using descriptive statistics and correlation tests. Results: Among 601 medical records reviewed, 239 participants met inclusion criteria, and 139 attended pharmacotherapy visits. A total of 277 DRPs were identified, averaging 1.99 DRPs per participant. The most common DRPs were the need for preventative therapy (37.2%), untreated conditions (15.9%), and laboratory monitoring (14.8%). A total of 443 recommendations were provided to participants, with an adherence rate of 76.4%. Among those who fully adhered to the recommendations, 97.2% of DRPs were resolved. While adherence was initially higher among female participants, overall compliance rates did not significantly differ by gender. Conclusion: Clinical pharmacist interventions effectively identified and resolved DRPs among pharmacy staff, improving medication management. These findings highlight the value of integrating clinical pharmacists into occupational health programs to enhance medication safety and adherence.
- Open Access
- 11 November 2024
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 18 (1) , 1-7
Immediate hypersensitivity reactions to parenteral cyclosporine in patients with thalassemia major undergoing hematopoietic stem cell transplantation: a case report and review of the literature
Allogeneic hematopoietic stem cell transplantation is a definitive cure for eligible patients with thalassemia major, and calcineurin inhibitors are essential for preventing graft-versus-host disease. Although invaluable, there are few reports of life-threatening hypersensitivity reactions associated with calcineurin inhibitors. These reactions are generally rare but seem to be more prevalent among patients with thalassemia. Herein, we retrospectively report four cases of patients with thalassemia major who developed hypersensitivity reactions to parenteral cyclosporine. The cases include one 19-year-old Caucasian female and three Caucasian males, aged 17, 10, and 20 years, respectively. The patients exhibited symptoms of varying severity, necessitating different management strategies. The reactions occurred either immediately or within a few minutes after the onset of cyclosporine infusion and were often worsened by rechallenge. In all cases, cyclosporine was eventually replaced with tacrolimus or sirolimus. A comprehensive literature review was conducted to investigate the basis of severe immunoglobulin E-mediated hypersensitivity reactions to calcineurin inhibitors in patients with thalassemia major undergoing hematopoietic stem cell transplantation. Several immunogenic factors may potentially increase the susceptibility of these patients to hypersensitivity reactions to Cremophor-containing medications. While severe reactions to calcineurin inhibitors remain rare, clinicians should be aware of the potential for serious adverse events in patients with thalassemia.
- 11 November 2024
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 18 (1) , 1-7
Open AccessImmediate hypersensitivity reactions to parenteral cyclosporine in patients with thalassemia major undergoing hematopoietic stem cell transplantation: a case report and review of the literature
Allogeneic hematopoietic stem cell transplantation is a definitive cure for eligible patients with thalassemia major, and calcineurin inhibitors are essential for preventing graft-versus-host disease. Although invaluable, there are few reports of life-threatening hypersensitivity reactions associated with calcineurin inhibitors. These reactions are generally rare but seem to be more prevalent among patients with thalassemia. Herein, we retrospectively report four cases of patients with thalassemia major who developed hypersensitivity reactions to parenteral cyclosporine. The cases include one 19-year-old Caucasian female and three Caucasian males, aged 17, 10, and 20 years, respectively. The patients exhibited symptoms of varying severity, necessitating different management strategies. The reactions occurred either immediately or within a few minutes after the onset of cyclosporine infusion and were often worsened by rechallenge. In all cases, cyclosporine was eventually replaced with tacrolimus or sirolimus. A comprehensive literature review was conducted to investigate the basis of severe immunoglobulin E-mediated hypersensitivity reactions to calcineurin inhibitors in patients with thalassemia major undergoing hematopoietic stem cell transplantation. Several immunogenic factors may potentially increase the susceptibility of these patients to hypersensitivity reactions to Cremophor-containing medications. While severe reactions to calcineurin inhibitors remain rare, clinicians should be aware of the potential for serious adverse events in patients with thalassemia.
- 2 September 2024
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 31 (8) , 1256-1263
Assessment of drug-drug interactions among patients with hematologic malignancy: A clinical pharmacist-led study
Introduction: Patients with hematologic malignancies often receive multiple medications, leading to potential drug-drug interactions (DDIs). Identifying and managing these DDIs is crucial for ensuring patient safety and effective care. This study aimed to identify and describe DDIs and associated factors in hematologic malignancy patients. Methods: This prospective interventional study was conducted at a referral center and included hospitalized patients with hematologic malignancies who were receiving at least four concurrent medications. A pharmacist initially compiled a comprehensive list of all medications through patient interviews and medication reviews, and subsequently, identified and categorized potential DDIs using the Lexi-interact ® and Micromedex ® databases. The clinical pharmacist then evaluated the clinical impact of the identified DDIs in every individual patient and provided appropriate interventions to resolve them. Results: A total of 200 patients met the inclusion criteria for the study, with 1281 DDIs identified across 337 distinct types. The majority of identified DDIs exhibited major severity (52.1%) and pharmacokinetic mechanisms (50.3%), with an unspecified onset (79.4%) and fair evidence (67%). Of the identified DDIs, 81.1% were considered clinically significant, prompting 1059 pharmacotherapy interventions by the clinical pharmacist. Additionally, a significant relationship was observed between the number of drugs used during hospitalization and the occurrence of DDIs (P < 0.001, r = 0.633). Conclusion: DDIs are highly prevalent among hospitalized patients with hematologic malignancies, with their occurrence increasing alongside the number of medications administrated. The intervention of a clinical pharmacist is crucial to evaluate the clinical impact of these DDIs and implement effective interventions for their management.
- 2 September 2024
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 31 (8) , 1256-1263
Assessment of drug-drug interactions among patients with hematologic malignancy: A clinical pharmacist-led study
Introduction: Patients with hematologic malignancies often receive multiple medications, leading to potential drug-drug interactions (DDIs). Identifying and managing these DDIs is crucial for ensuring patient safety and effective care. This study aimed to identify and describe DDIs and associated factors in hematologic malignancy patients. Methods: This prospective interventional study was conducted at a referral center and included hospitalized patients with hematologic malignancies who were receiving at least four concurrent medications. A pharmacist initially compiled a comprehensive list of all medications through patient interviews and medication reviews, and subsequently, identified and categorized potential DDIs using the Lexi-interact ® and Micromedex ® databases. The clinical pharmacist then evaluated the clinical impact of the identified DDIs in every individual patient and provided appropriate interventions to resolve them. Results: A total of 200 patients met the inclusion criteria for the study, with 1281 DDIs identified across 337 distinct types. The majority of identified DDIs exhibited major severity (52.1%) and pharmacokinetic mechanisms (50.3%), with an unspecified onset (79.4%) and fair evidence (67%). Of the identified DDIs, 81.1% were considered clinically significant, prompting 1059 pharmacotherapy interventions by the clinical pharmacist. Additionally, a significant relationship was observed between the number of drugs used during hospitalization and the occurrence of DDIs (P < 0.001, r = 0.633). Conclusion: DDIs are highly prevalent among hospitalized patients with hematologic malignancies, with their occurrence increasing alongside the number of medications administrated. The intervention of a clinical pharmacist is crucial to evaluate the clinical impact of these DDIs and implement effective interventions for their management.
- 1 June 2024
- Published by Bentham Science Publishers Ltd. in Current Drug Therapy
- Vol. 19 (4) , 385-393
Optimal Weight-based Dosing of Intravenous Immunoglobulin (IVIG) among Overweight and Obese Patients
Intravenous immunoglobulin (IVIG), as an expensive medication under a national shortage, has been widely used for the treatment of several autoimmune diseases and immunodeficiency syndromes. Although conducting studies on therapeutic indications of IVIG has increased significantly, a limited number of researches have investigated individualized dosing in terms of the drug, disease state, and some patient-specific factors like obesity. The objective of the review was to describe the impact of various weight-based dosing regimens on the pharmacokinetics parameters, efficacy, safety, and cost of IVIG and to choose the best dosing approach for obese patients. Thirteen of the total 128 manuscripts collected, reviewed, and analyzed were found from Scopus, PubMed, and Google scholar. The evidence suggests that obesity may have an impact on IVIG pharmacokinetics, safety, and efficacy. The logical approach is to initial the dose based on the ideal or adjusted body weight and then modify the maintenance dose according to the patient's clinical response.
- 1 June 2024
- Published by Bentham Science Publishers Ltd. in Current Drug Therapy
- Vol. 19 (4) , 385-393
Optimal Weight-based Dosing of Intravenous Immunoglobulin (IVIG) among Overweight and Obese Patients
Intravenous immunoglobulin (IVIG), as an expensive medication under a national shortage, has been widely used for the treatment of several autoimmune diseases and immunodeficiency syndromes. Although conducting studies on therapeutic indications of IVIG has increased significantly, a limited number of researches have investigated individualized dosing in terms of the drug, disease state, and some patient-specific factors like obesity. The objective of the review was to describe the impact of various weight-based dosing regimens on the pharmacokinetics parameters, efficacy, safety, and cost of IVIG and to choose the best dosing approach for obese patients. Thirteen of the total 128 manuscripts collected, reviewed, and analyzed were found from Scopus, PubMed, and Google scholar. The evidence suggests that obesity may have an impact on IVIG pharmacokinetics, safety, and efficacy. The logical approach is to initial the dose based on the ideal or adjusted body weight and then modify the maintenance dose according to the patient's clinical response.